Haemophilia - chronic management & prophylaxis
haemophilia mgmt · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
X-linked deficiency of factor VIII (A) or IX (B) causing recurrent joint and soft-tissue bleeding. Modern care centres on prophylaxis to prevent arthropathy using factor concentrates, extended-half-life products, or non-factor agents such as emicizumab.
Red flags
- Head injury or suspected intracranial bleed (treat before imaging)
- Rising inhibitor titre with failure to respond to factor
- Compartment syndrome from muscle bleed
- Throat/neck or retroperitoneal bleeding
- Acute haemarthrosis with fixed joint
Assessment
Differential diagnosis
- Von Willebrand disease
- Acquired haemophilia
- Other factor deficiencies
- Platelet disorder
- Vitamin K deficiency
Investigations
- Coagulation screen (prolonged APTT, normal PT)
- Factor VIII or IX assay to grade severity
- Inhibitor assay (Bethesda) regularly and before surgery
- Genetic testing for carrier/prenatal counselling
- Joint imaging (MRI/ultrasound) for arthropathy
- Viral screen (historic blood-product exposure)
Management
- Confirm diagnosis, factor type and severity (severe <1%, moderate 1-5%, mild >5-40%)
- Enrol in a comprehensive haemophilia centre with multidisciplinary care
- Offer prophylaxis for severe disease to keep factor levels above the bleeding threshold and prevent arthropathy
- Choose regimen: standard or extended-half-life factor concentrate, or emicizumab (FVIII mimetic) for haemophilia A with or without inhibitors
- Teach home treatment and rapid factor replacement for breakthrough bleeds
- Monitor for inhibitor development, especially early in treatment
- Manage inhibitors with bypassing agents and immune tolerance induction
- Provide physiotherapy, joint protection and manage established arthropathy
- Avoid intramuscular injections, NSAIDs and antiplatelets; vaccinate subcutaneously
- Consider gene therapy in eligible adults and give genetic counselling
Drugs & doses
Recombinant factor VIII prophylaxis 20-40 IU/kg IV 2-3 times/week (haemophilia A)
Recombinant factor IX prophylaxis 40-60 IU/kg IV 1-2 times/week (haemophilia B)
Emicizumab load 3 mg/kg SC weekly x4 then 1.5 mg/kg weekly (or 3 mg/kg q2wk / 6 mg/kg q4wk)
Tranexamic acid 1 g PO/IV three times daily for mucosal bleeding (avoid with aPCC)
Disposition
Comprehensive haemophilia centre; home therapy with 24-hour access; admit for major or CNS bleeds.
Complications & pitfalls
- Chronic haemophilic arthropathy
- Inhibitor development
- Intracranial haemorrhage
- Transfusion-transmitted infection (historic)
- Thrombotic risk if emicizumab combined with high-dose aPCC
Exam pearls
- Treat a suspected head bleed with factor immediately, before imaging
- Emicizumab transforms care but renders APTT-based monitoring and aPCC dosing hazardous
- Early prophylaxis prevents the disabling arthropathy of severe disease
- Never give IM injections or NSAIDs
- Inhibitors are the biggest modern treatment challenge - monitor Bethesda titres
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.